EXPLORE!

FDA expands approval of Sutent to reduce the risk of recurrence of kidney cancer

  887 Views

#General Surgery  #Nephrology 

eMediNexus    18 November 2017

The US Food and Drug Administration FDA has approved Sutent sunitinib malate for the adjuvant treatment of adult patients who are at a high risk of kidney cancer renal cell carcinoma returning after a kidney has been removed nephrectomy . Adjuvant treatment is a form of therapy that is taken after an initial surgical removal to lower the risk of the cancer coming back.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.